Lapisteride

Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase.[2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia,[2][3] but was never marketed.

Lapisteride
Clinical data
Routes of
administration
Oral[1]
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC29H40N2O3
Molar mass464.650 g·mol−1
3D model (JSmol)
  (verify)

See also

References

  1. Yada S, Ohya M, Ohuchi Y, et al. (April 2003). "Solid phase transition of CS-891 enantiotropes during grinding". International Journal of Pharmaceutics. 255 (1–2): 69–79. doi:10.1016/S0378-5173(03)00084-X. PMID 12672603.
  2. Niiyama S, Kojima K, Hamada T, Happle R, Hoffmann R (December 2000). "The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles". European Journal of Dermatology. 10 (8): 593–5. PMID 11125319.
  3. Bernan; British Pharmacopoeia Commission (February 2002). British Approved Names 2002. The Stationery Office. p. 157. ISBN 978-0-11-322558-3. Retrieved 17 November 2011.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.